{
  "$schema": "folio-library-entry/v1",
  "id": "10665-331170",
  "blocks": [
    {
      "id": "library/10665-331170/blocks/prose-sec-front-matter",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Front matter",
      "pageStart": 1,
      "pageEnd": 5,
      "target": "../sections/sec-front-matter.md",
      "narrative": null,
      "content": "WHO \nconsolidated \nguidelines on\ntuberculosis\nModule 1: Prevention\nTuberculosis preventive treatment\n© World Health Organization 2020\nSome rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence \n(CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). \nUnder the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is \nappropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific orga",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The title, copyright, licence and cataloguing pages of the WHO consolidated guidelines on tuberculosis, Module 1: prevention, on TB preventive treatment (2020), with ISBNs.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-331170/blocks/prose-sec-000",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Table of Contents",
      "pageStart": 5,
      "pageEnd": 6,
      "target": "../sections/sec-000-table-of-contents.md",
      "narrative": null,
      "content": "Acknowledgements\b\niv\nAbbreviations & acronyms\b\nvi\nDefinitions\b\nvii\nExecutive summary\b\nviii\nIntroduction\b\n1\n1. Recommendations\b\n3\n2. Monitoring and evaluation\b\n26\n3. Research gaps\b\n28\n4. References\b\n31\nSupplementary Table\b\n38\nOnline annexes\nAnnex 1. Methods and Expert panels\nAnnex 2. GRADE Summary of Evidence Tables\nAnnex 3. GRADE Evidence to Decision Tables",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The table of contents of the 2020 WHO guidelines on TB preventive treatment, listing chapters and online annexes.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-331170/blocks/prose-sec-001",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Acknowledgements",
      "pageStart": 6,
      "pageEnd": 8,
      "target": "../sections/sec-001-acknowledgements.md",
      "narrative": null,
      "content": "The production of the WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment \nwas coordinated and written by Dennis Falzon, Avinash Kanchar and Matteo Zignol under the \noverall direction of Tereza Kasaeva, Director of the WHO Global TB Programme. The WHO Global \nTB Programme gratefully acknowledges the contribution of all experts involved in the production of \nthese guidelines.1\nGuideline Development Group\nThe Guideline Development Group (GDG) was composed of Mohammed Al Lawati (Consultant \nPhysician, Oman); Helen Ayles (Infectious Diseases and International Health, LSH",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Acknowledges the WHO Global TB Programme staff who coordinated the guidelines and lists the members of the Guideline Development Group and other contributors. It also thanks the Guideline Review Committee and names USAID and the Russian Federation as funders of the 2019–2020 update. The names and affiliations come from many countries.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-331170/blocks/prose-sec-002",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Abbreviations & acronyms",
      "pageStart": 8,
      "pageEnd": 9,
      "target": "../sections/sec-002-abbreviations-acronyms.md",
      "narrative": null,
      "content": "1HP\t\nOne month of daily rifapentine plus isoniazid \n3HP\t\nThree months of weekly rifapentine plus isoniazid \n3HR\t\nThree months of daily rifampicin plus isoniazid\n4R\t\nFour months of daily rifampicin monotherapy\n6H\t\nSix months of daily isoniazid monotherapy\n9H\t\nNine months of daily isoniazid monotherapy\nART\t\nantiretroviral treatment\nBCG\t\nbacille Calmette-Guérin (vaccine)\nCI\t\nconfidence interval\nERG\t\nExternal Review Group\nGDG\t\nGuideline Development Group    \nGRADE\t\ngrading of recommendations assessment, development and evaluation\nHIV\t\nhuman immunodeficiency virus\nHr-TB\t\nisoniazid-resistant, rifamp",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A list of abbreviations and acronyms used in the TB preventive treatment guidelines, including regimen codes such as 3HP and 1HP.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-331170/blocks/prose-sec-003",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Definitions",
      "pageStart": 9,
      "pageEnd": 10,
      "target": "../sections/sec-003-definitions.md",
      "narrative": null,
      "content": "Definitions\nNote: The definitions listed below apply to the terms as used in these guidelines. They may have different \nmeanings in other contexts.\nAdolescent: A person aged 10–19 years\nAdult: A person over 19 years of age\nBacteriologically confirmed TB: TB diagnosed in a biological specimen by smear microscopy, culture \nor a WHO-approved molecular test such as Xpert® MTB/RIF\nChild: A person under 10 years of age\nContact: Any person who was exposed to a person with tuberculosis\nContact investigation: A systematic process for identifying previously undiagnosed people with TB \namong the contacts",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Defines terms used in the TB preventive treatment guidelines, such as age groups, contact investigation, household contact and high TB transmission setting. It also defines TB disease as distinct from TB infection and underweight in adults and children.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-331170/blocks/prose-sec-004",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Executive summary",
      "pageStart": 10,
      "pageEnd": 14,
      "target": "../sections/sec-004-executive-summary.md",
      "narrative": null,
      "content": "Latent tuberculosis infection (LTBI) is defined as a state of persistent immune response to stimulation \nby M. tuberculosis antigens with no evidence of clinically manifest active TB. It is estimated that about \na quarter of the world’s population is infected with TB. TB preventive treatment (TPT) is one of the \nkey interventions recommended by WHO to achieve the End TB Strategy targets, as upheld by the \nUN High Level Meeting on TB in September 2018. TPT fits within a larger framework of preventive \nactions envisaged by Pillars 1 and 2 of the End TB Strategy, ranging from screening for active",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The executive summary of the 2020 guidelines, defining latent TB infection, noting that about a quarter of the world's population is infected, and placing preventive treatment within the End TB Strategy. It describes the intended users and the aims of the update. It lists the main changes, including recommendations reworded to apply regardless of TB burden, adding 1-month rifapentine plus isoniazid and 4-month rifampicin as options in all settings, and simplified regimen durations. It also notes that a single algorithm replaces four earlier ones and that references and research gaps were updated.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-331170/blocks/table-001",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 1. Recommendations in the WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment²",
      "pageStart": 11,
      "pageEnd": 12,
      "target": "../tables/table-1.csv",
      "narrative": "draft",
      "content": "The table lists the 18 recommendations of the WHO consolidated guidelines on tuberculosis preventive treatment, grouped into four sections: identifying populations for LTBI testing and TB preventive treatment (people living with HIV, household contacts, other people at risk), algorithms to rule out active TB disease, testing for LTBI, and TB preventive treatment options.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-331170/blocks/prose-sec-005",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Introduction",
      "pageStart": 14,
      "pageEnd": 14,
      "target": "../sections/sec-005-introduction.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-331170/blocks/prose-sec-006",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Background",
      "pageStart": 14,
      "pageEnd": 14,
      "target": "../sections/sec-006-1-background.md",
      "narrative": null,
      "content": "Latent tuberculosis infection (LTBI) is defined as a state of persistent immune response to stimulation \nby M. tuberculosis antigens with no evidence of clinically manifest active TB (1)3. As there is no “gold \nstandard” test for TB infection, the global burden is not known with certainty; however, about one \nfourth of the world’s population is estimated to be infected with M. tuberculosis (2),(3). The vast \nmajority have no signs or symptoms of TB disease and are not infectious, although they are at risk \nof developing active TB disease and becoming infectious. Several studies have shown that",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Gives background on latent TB infection, noting that 5–10% of those infected develop active disease, usually within five years, and that immune status is the main risk factor. It recalls the 2018 UN high-level meeting commitment to provide preventive treatment to 30 million people by 2022 and places it within the End TB Strategy.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-331170/blocks/prose-sec-007",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Rationale",
      "pageStart": 14,
      "pageEnd": 15,
      "target": "../sections/sec-007-2-rationale.md",
      "narrative": null,
      "content": "WHO guidelines on PMTPT are premised upon the probability that the condition will progress to active \nTB disease in specific risk groups, on the underlying epidemiology and burden of TB, the feasibility of \nthe intervention, and the likelihood of a broader public health impact. They are expected to provide \nthe basis for the development of national guidelines for LTBI management, adapted to the local \ncircumstances. Although these revised guidelines envisage a massive expansion in population level \ntreatment of LTBI, global coverage of the intervention is still very low even in the priority ta",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains the rationale for the guidelines, which weigh risk of progression, TB burden, feasibility and public health impact and are meant to be adapted nationally. It notes low global coverage and that new evidence since the 2018 consolidated guidelines required revisiting some recommendations.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-331170/blocks/prose-sec-008",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Scope of the current update",
      "pageStart": 15,
      "pageEnd": 15,
      "target": "../sections/sec-008-3-scope-of-the-current-update.md",
      "narrative": null,
      "content": "The current update considered evidence for three questions, worded in PICO format4, namely:\n•\t In people of all ages at risk of active TB, does a 4-month daily rifampicin regimen safely prevent \nTB disease compared to other recommended TB preventive treatment regimens? (PICO 6)\n•\t In people of all ages at risk of active TB, does a 1-month daily rifapentine plus isoniazid regimen \nsafely prevent TB disease compared to other recommended TB preventive treatment regimens? \n(PICO 7)\n•\t In pregnant and postpartum women, is isoniazid preventive treatment for TB as safe as other \npreventive treatment",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the scope of the update, which addressed three PICO questions on 4-month rifampicin, 1-month rifapentine plus isoniazid, and isoniazid safety in pregnant and postpartum women. It notes that wording was clarified and that the earlier distinction between high- and low-incidence settings was reconsidered, with evidence judged using GRADE evidence-to-decision criteria.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-331170/blocks/prose-sec-009",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Target audience",
      "pageStart": 15,
      "pageEnd": 16,
      "target": "../sections/sec-009-4-target-audience.md",
      "narrative": null,
      "content": "The WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment provides a \ncomprehensive set of recommendations for PMTPT geared towards the implementers of the WHO \nEnd TB Strategy and also for countries intent upon TB elimination (9). The guidelines are to be \nused primarily in national TB and HIV and maternal and child programmes or their equivalents in \nministries of health and for other policy-makers working on TB, HIV, infectious diseases and maternal \nand child health. They are also appropriate for staff of ministries of justice, correctional services and \nother gove",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Identifies the target audience as national TB, HIV and maternal and child health programmes and other policy-makers, staff of agencies such as prison and immigration services, and clinicians in public and private sectors.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-331170/blocks/prose-sec-010",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Recommendations",
      "pageStart": 16,
      "pageEnd": 39,
      "target": "../sections/sec-010-1-recommendations.md",
      "narrative": null,
      "content": "1.1.\tIdentification of populations for testing of latent \ntuberculosis infection and TB preventive treatment\nAmong individuals infected with M. tuberculosis it is estimated that the lifetime risk of progressing to \nactive TB averages to about 5–10% (4). The risk is particularly elevated among children under the age \nof 5 years and among people with compromised immunity (1). As any treatment entails risk of harms \nand opportunity costs, TB preventive treatment should be selectively targeted to population groups \nat highest risk of progression to active TB disease, who would benefit most from it",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The main recommendations chapter of the 2020 TB preventive treatment guidelines, which begins by explaining why preventive treatment should target groups at highest risk of progression. It gives recommendations and supporting evidence for adults, adolescents, infants and children living with HIV, citing trial data on reduced TB risk and added benefit alongside antiretroviral therapy. The chapter goes on to cover other risk groups, testing and treatment options across a long, cut section. It ends with preventive treatment for contacts of people with multidrug-resistant TB, advising individualized fluoroquinolone-based regimens and written informed consent given very low-certainty evidence.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-331170/blocks/table-002",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 2. Pooled estimates of risk for active TB among household contacts stratified by age and baseline LTBI status as compared with the general population",
      "pageStart": 19,
      "pageEnd": 19,
      "target": "../tables/table-2.csv",
      "narrative": "draft",
      "content": "The table gives pooled risk ratios (with confidence intervals) and numbers of studies for progression to active TB among household contacts aged 0–4, 5–14 and ≥ 15 years, compared with the general population as reference. Estimates are shown for contacts who were LTBI-positive at baseline and for all contacts regardless of baseline LTBI status, at follow-up of under 12 and under 24 months.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-331170/blocks/figure-vfig-p028",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 28,
      "pageEnd": 28,
      "target": "../figures/vfig-p028.webp",
      "narrative": "draft",
      "content": "Flowchart (printed rotated 90°) of the algorithm for LTBI testing and TB preventive treatment in individuals at risk (Fig. 1), with three entry groups: HIV positive, household contact and other risk group. People living with HIV with any symptom (current cough, fever, weight loss or night sweats), and symptomatic household contacts, are investigated for active TB; household contacts aged 5 years and over and other risk groups go to TST or IGRA, and if positive or unavailable to chest X-ray, with an abnormal result leading to investigation for active TB. Those without active TB are assessed for contraindications to preventive treatment, which is then given or deferred, with follow-up for active TB as necessary even after completing preventive treatment.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-331170/blocks/table-003",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 3. Recommended dosages of medicines for TB preventive treatment",
      "pageStart": 36,
      "pageEnd": 36,
      "target": "../tables/table-3.csv",
      "narrative": "draft",
      "content": "The table gives the recommended doses of medicines for each TB preventive treatment regimen (6H/9H, 4R, 3HR, 3HP, 1HP and six months of levofloxacin for MDR-TB contacts), by age and, where relevant, body weight. For 3HP it gives the number of isoniazid and rifapentine tablets per weight band for ages 2–14 years and over 14 years.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-331170/blocks/prose-sec-011",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Monitoring and evaluation",
      "pageStart": 39,
      "pageEnd": 41,
      "target": "../sections/sec-011-2-monitoring-and-evaluation.md",
      "narrative": null,
      "content": "2. Monitoring and evaluation\nCoverage of contact investigation and TB preventive treatment among child contacts and PLHIV are \namong the top 10 core indicators for monitoring implementation of the End TB Strategy (8). National \nTB and HIV programmes report data yearly to WHO and UNAIDS on progress in LTBI care in target \npopulations. PMTPT should include monitoring and evaluation systems that are aligned with national \npatient monitoring and surveillance systems (103),(104). Appropriate recording and reporting tools \nshould be developed and electronic case-based monitoring will facilitate LTBI",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes monitoring and evaluation of programmatic TB preventive treatment, including core indicators, national recording and reporting systems and involving the private sector. It covers adverse drug reactions, monthly follow-up, warning symptoms of hepatotoxicity and when baseline liver testing is advised. It ends with clinical follow-up of contacts exposed to multidrug-resistant TB for at least two years and attention to drug interactions.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-331170/blocks/prose-sec-012",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Research gaps",
      "pageStart": 41,
      "pageEnd": 44,
      "target": "../sections/sec-012-3-research-gaps.md",
      "narrative": null,
      "content": "3. Research gaps\nThe evidence reviewed ahead of the current update exposed additional knowledge gaps to the ones \nreported in other recent updates of the guidelines. Continued research on development and on \nimplementation science remain critical for many aspects of the PMTPT. Some of this information may \nbe collected as part of user feedback put in place by the implementing programme.\nRisks for progression to active TB\nEvidence on the likelihood of progression from infection to active TB in different at-risk populations \nwill help determine the potential benefits of TB preventive treatment a",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out research gaps in TB preventive treatment, including risk of progression in groups such as people with diabetes or who smoke, and better algorithms for ruling out active TB. It calls for improved diagnostic tests for infection and shorter, better-tolerated regimens, with more data on rifapentine in young children and pregnancy. It also lists needs on implementation, contact tracing strategies and monitoring tools.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-331170/blocks/prose-sec-013",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "References",
      "pageStart": 44,
      "pageEnd": 51,
      "target": "../sections/sec-013-4-references.md",
      "narrative": null,
      "content": "1.\t Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis Infection. N Engl J \nMed. 2015 May 28;372(22):2127–35. \n2.\t Dodd PJ, Gardiner E, Coghlan R, Seddon JA. Burden of childhood tuberculosis in 22 high-burden countries: \na mathematical modelling study. Lancet Glob Health. 2014 Aug;2(8):e453–9. \n3.\t Houben RMGJ, Dodd PJ. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using \nMathematical Modelling. PLOS Medicine. 2016 Oct 25;13(10):e1002152. \n4.\t Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childho",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The reference list for the TB preventive treatment guidelines, with over 100 citations to journal studies and WHO and UN documents on TB infection, treatment and policy.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-331170/blocks/prose-sec-014",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Supplementary Table",
      "pageStart": 51,
      "pageEnd": 56,
      "target": "../sections/sec-014-supplementary-table.md",
      "narrative": null,
      "content": "Supplementary Table\nSummary of changes to the WHO TB preventive treatment recommendations between 2018 and current updates\nNote: In the current update, two of the 2018 recommendations on LTBI testing (Section C) were incorporated into the remarks as implementation \nconsiderations; four recommendations on individual TB preventive treatment options have been merged into one recommendation (Recommendation 17). \nRecommendations 3, 6, 9, 17 and 18 may apply to specific settings in a country regardless of the overall national TB incidence (see text and Annexes for \nfurther explanation of the changes",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A supplementary table comparing WHO's 2018 recommendations on tuberculosis preventive treatment with those in the current update, section by section. A note explains that two LTBI testing recommendations became implementation remarks and that four regimen recommendations were merged into one. Each row pairs the old and new wording for groups such as people living with HIV, infants and children, and household contacts, marking whether changes were language edits or substantive. It closes with the recommendation on 36 months of isoniazid in high-transmission settings and WHO Global TB Programme contact details.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    }
  ]
}
